Mode
Text Size
Log in / Sign up
Phase 3 Completed N=66 Randomized Triple-blind Treatment

Laser Acupuncture for Postpartum Weight Retention

Postpartum Weight Retention
Source: ClinicalTrials.gov NCT02840916 ↗
Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcomePrimary: Body Mass Index (BMI) — 33.62; 28.03; 26.90; 26.99 kg/m^2
◆ Published Evidence
Established
37citations · ~2 / year
Clinical observations on laser acupuncture in simple obesity therapy.
The American journal of Chinese medicine · 2010 · High-confidence link

Summary

Objective: To determine the therapeutic effect of acupuncture on postpartum weight retention. Methods: 66 subjects after delivery with postpartum weight retention will be randomly divided into laser acupuncture and control group. A single-blind clinical trial will be conducted and the subjects will be treated with verum or sham laser acupuncture 5 sessions per week. After about 3 weeks of treatment, the differences of the subjects' body weight, body mass index, and waist circumference will be analyzed with ANOVA between laser acupuncture and control group.

Linked Publications

  • Clinical observations on laser acupuncture in simple obesity therapy.
    The American journal of Chinese medicine · 2010 · 37 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Body Mass Index (BMI)
33.62; 28.03; 26.90; 26.99; 26.16; 26.64
SECONDARY
Waist-to-buttock Ratio (WBR)
0.93; 0.92; 0.92; 0.90
SECONDARY
Body Fat Percentage (BFP)
36.94; 36.02; 35.75; 35.37

Eligibility Criteria

Inclusion Criteria

  • postpartum duration of 25;
  • age > 20 years;
  • did not use any other medications for weight loss during the study period; and
  • provided informed consent.

Exclusion Criteria

  • presence of a pacemaker;
  • history of seizure or epilepsy;
  • taking immunosuppressant medication;
  • cancer;
  • infectious disease of the skin;
  • taking medications for weight loss, including Chinese herbal preparations, during the study period;
  • receiving other treatment, including supplements, herbs, and medications for weight gain prior to entering the study;
  • comorbidities (hypothyroidism, renal disease, etc.) that the physician believes would affect the findings;
  • unable to undergo LAT due to other medical conditions; and
  • lack of informed consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02840916) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search